title: Oncogenic Kit signaling and therapeutic intervention in a mouse model of gastrointestinal stromal tumor.
abstract: Kit receptor-activating mutations are critical in the pathogenesis of gastrointestinal stromal tumors (GIST). We investigated mechanisms of oncogenic Kit signaling and the consequences of therapeutic intervention in a mouse model of human GIST. Treatment of GIST mice with imatinib decreased cell proliferation and increased apoptosis in the tumor. Analysis of tumor tissue from imatinib-treated mice showed diminished phosphatidylinositol 3-kinase (PI3-kinase) and mammalian target of rapamycin (mTOR) signaling suggesting that oncogenic Kit signaling critically contributes to the translational response in GIST. Treatment with RAD001 (everolimus), an mTOR inhibitor, diminished the translational response and cell proliferation in tumor lesions, pointing to mTOR inhibition as a therapeutic approach for imatinib-resistant GIST. Analysis of RNA expression profiles in GIST lesions with and without imatinib treatment showed changes in expression of IFN-inducible genes and cell cycle regulators. These results convincingly show that KitV558Delta/+ mice represent a unique faithful mouse model of human familial GIST, and they demonstrate the utility of these mice for preclinical investigations and to elucidate oncogenic signaling mechanisms by using genetic approaches and targeted pharmacological intervention.
authors.affiliation: Department of Developmental Biology, Computational Biology Center, and Molecular Cytology Facility, Sloan-Kettering Institute, New York, NY 10021, USA.
authors.forename: Ferdinand
authors.initials: F
authors.lastname: Rossi
authors.forename: Imke
authors.initials: I
authors.lastname: Ehlers
authors.forename: Valter
authors.initials: V
authors.lastname: Agosti
authors.forename: Nicholas D
authors.initials: ND
authors.lastname: Socci
authors.forename: Agnes
authors.initials: A
authors.lastname: Viale
authors.forename: Gunhild
authors.initials: G
authors.lastname: Sommer
authors.forename: Yasemin
authors.initials: Y
authors.lastname: Yozgat
authors.forename: Katia
authors.initials: K
authors.lastname: Manova
authors.forename: Cristina R
authors.initials: CR
authors.lastname: Antonescu
authors.forename: Peter
authors.initials: P
authors.lastname: Besmer
mesh_terms: D000818:Animals; D001549:Benzamides; D049109:Cell Proliferation / Q000187:drug effects; D004195:Disease Models, Animal; D015536:Down-Regulation; D000068338:Everolimus; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D000068877:Imatinib Mesylate; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D010766:Phosphorylation; D010879:Piperazines / Q000627:therapeutic use; D011494:Protein Kinases / Q000378:metabolism; D019009:Proto-Oncogene Proteins c-kit / Q000235:genetics / Q000378:metabolism*; D011743:Pyrimidines / Q000627:therapeutic use; D015398:Signal Transduction; D020123:Sirolimus / Q000031:analogs & derivatives / Q000627:therapeutic use; D058570:TOR Serine-Threonine Kinases
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D000068338:Everolimus; D011494:Protein Kinases; C546842:MTOR protein, human; C546843:mTOR protein, mouse; D019009:Proto-Oncogene Proteins c-kit; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus